HPRT Deficiency Coordinately Dysregulates Canonical Wnt and Presenilin-1 Signaling: A Neuro-Developmental Regulatory Role for a Housekeeping Gene? by Kang, Tae Hyuk et al.
HPRT Deficiency Coordinately Dysregulates Canonical
Wnt and Presenilin-1 Signaling: A Neuro-Developmental
Regulatory Role for a Housekeeping Gene?
Tae Hyuk Kang, Ghiabe-Henri Guibinga, Theodore Friedmann*
Department of Pediatrics, Center for Neural Circuit and Behavior and San Diego Rady Children’s Hospital, University of California San Diego, San Diego School of Medicine,
La Jolla, California, United States of America
Abstract
We have used microarray-based methods of global gene expression together with quantitative PCR and Western blot
analysis to identify dysregulation of genes and aberrant cellular processes in human fibroblasts and in SH-SY5Y
neuroblastoma cells made HPRT-deficient by transduction with a retrovirus stably expressing an shRNA targeted against
HPRT. Analysis of the microarray expression data by Gene ontology (GO) and Gene Set Enrichment Analysis (GSEA) as well as
significant pathway analysis by GeneSpring GX10 and Panther Classification System reveal that HPRT deficiency is
accompanied by aberrations in a variety of pathways known to regulate neurogenesis or to be implicated in
neurodegenerative disease, including the canonical Wnt/b-catenin and the Alzheimer’s disease/presenilin signaling
pathways. Dysregulation of the Wnt/b-catenin pathway is confirmed by Western blot demonstration of cytosolic
sequestration of b-catenin during in vitro differentiation of the SH-SY5Y cells toward the neuronal phenotype. We also
demonstrate that two key transcription factor genes known to be regulated by Wnt signaling and to be vital for the
generation and function of dopaminergic neurons; i.e., Lmx1a and Engrailed 1, are down-regulated in the HPRT knockdown
SH-SY5Y cells. In addition to the Wnt signaling aberration, we found that expression of presenilin-1 shows severely aberrant
expression in HPRT-deficient SH-SY5Y cells, reflected by marked deficiency of the 23 kDa C-terminal fragment of presenilin-1
in knockdown cells. Western blot analysis of primary fibroblast cultures from two LND patients also shows dysregulated
presenilin-1 expression, including aberrant proteolytic processing of presenilin-1. These demonstrations of dysregulated
Wnt signaling and presenilin-1 expression together with impaired expression of dopaminergic transcription factors reveal
broad pleitropic neuro-regulatory defects played by HPRT expression and suggest new directions for investigating
mechanisms of aberrant neurogenesis and neuropathology in LND and potential new targets for restoration of effective
signaling in this neuro-developmental defect.
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Introduction
Lesch-Nyhan disease (LND) is a generalized monogenic inborn
error of metabolism caused by deficiency of the purine
reutilization enzyme hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT) activity. The disease is characterized by two major
sets of defects; i.e., systemic purine metabolism expressed as
hyperuricemia, gouty arthritis and renal calculi [1], and
dysfunction of basal ganglia and other neural pathways associated
with the hallmark biochemical defect in HPRT deficiency; i.e.,
markedly reduced neurotransmitter dopamine (DA) in the basal
ganglia in both the human and mouse HPRT-deficient brain and
resulting dystonia [2]. Evidence has been presented that the basal
ganglia DA defect is associated with intrinsic defects in DA
neurons [3,4]. Although the mechanisms of the purine metabolic
aberrations are well understood, the mechanisms by which they
lead to neural dysfunction are poorly understood.
Many studies have examined the connection between defective
purine salvage and the loss of basal ganglia DA in LND and have
suggested a number of possible mechanisms by which HPRT
deficiency might lead to defective development or function of the
DA pathways and DA neurons, including abnormal nigrostriatal
axonal arborization or early axonal and neuronal degeneration
[5–9], secondary metabolic changes that may increase oxidative
stress [10,11] or impaired proteasomal function and protein mis-
folding that may generate molecules particularly toxic in DA
neurons [12]. The relationship between HPRT deficiency and
impaired DA neuron development has been partially clarified by
recent studies that have demonstrated that HPRT deficiency leads
to broad alterations of DA neuron-related transcription factors
and aberrant neurite outgrowth and cellular morphology in mouse
MN9D DA neuroblastoma and human NT2 embryonic carcino-
ma undergoing neuronal differentiation in vitro [13,14]. More-
over, a more recent report has confirmed similar transcriptional
aberrations in HPRT-deficient human neural stem cells [15].
These published studies point to aberrant generation of DA
neurons in HPRT deficiency, but a detailed understanding of the
aberrant regulation of DA neuron development and function in
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16572HPRT deficiency awaits clarification of the complex interplay
among multiple transcription and signaling factors that determines
generation and differentiation of the DA pathways and midbrain
DA neurons.
We have previously published an initial comparative charac-
terization of the transcriptomes of normal and HPRT-deficient
mouse striata and normal and LND human fibroblasts [16]. In
those studies, we identified a number of genes and gene sets whose
expression is dysregulated in HPRT-deficient mouse striatum. To
avoid the inevitable interpretational difficulties caused by genetic
heterogeneity of individual patient and normal control samples, we
have now examined the transcriptional aberrations in the less
complex system of wild type (WT) human fibroblasts and human
SH-SY5Y neuroblastoma cells in which HPRT expression is
efficiently knocked down by transduction with a retrovirus vector
expressing a short hairpin RNA targeted to HPRT. We have
identified a number of significantly altered signaling pathways in
HPRT-deficient cells, and in this report, we concentrate on
aberrations related to the Wnt and presenilin (PS) -1 signaling
pathways.
Wnt signaling mediates and controls many aspects of vertebrate
development approximately 19 different mammalian Wnt glyco-
proteins regulate many biological processes including embryonic
patterning, stem cell self renewal and differentiation, neurogenesis
and neural pathway development, tumorigenesis, and others
[17–21]. Wnt signaling is now recognized to play a key regulatory
role in proliferation and differentiation of DA precursors during
ventral midbrain (VM) neurogenesis, affecting many processes
required for the development of DA neurons from neural stem
cells and specification of their properties and functions, including
axon guidance and neurogenesis and synapse formation. Recently,
evidence has accumulated that dysfunction of these Wnt signaling
pathways plays a role in the induction of damage to the DA
pathways at the heart of Parkinson’s disease, and special attention
has been paid to the key role played by Wnt signaling in regulating
DA neurogenesis [22], at least partly through the regulation of key
transcription factors such as Lmx1a which in turn activate
downstream transcription factors to promote differentiation and
maturation of the mesencephalic DA neurons. A variety of Wnt
molecules such as Wnt1, Wnt3A, Wnt 5A and others have all been
shown to promote different aspects of VM morphogenesis such as
enhanced DA precursor differentiation, increased survival,
neurogenesis and other effects. Signaling by these and other forms
of Wnt occurs largely by three separate major pathways; i.e., the
canonical pathway mediated by b-catenin and the two non-
canonical WNT-PCP and the Wnt-Ca
++ pathways [23,24].
A second signaling pathway with important effects on the Wnt
signaling pathway is that associated with PS-1. Defects in this
pathway not only play a causal role in forms of familial
Alzheimer’s disease [25,26] but also interact with the canonical
Wnt signaling pathway by stabilizing b-catenin and regulating its
transcription [26]. These interactions between the Wnt and PS-1
signaling pathways suggest that they may cooperate in the
pathogenesis of some human neurodegenerative and neurodevel-
opmental diseases, possibly even playing a role in LND. If PS-1
dysregulation indeed is a factor in the development of neuropa-
thology in HPRT deficiency, it seems unlikely that its role is
through accumulation of a toxic Ab42, since no histopathological
evidence has ever been provided for accumulation of Ab or other
storage materials in the brain of LND patients or in the HPRT
knockout mouse.
We now provide evidence that HPRT deficiency produces
aberrations in both the canonical Wnt/b-catenin signaling as
reflected by elevated levels of cytosolic phosphorylated b-catenin,
markedly impaired nuclear transport of b-catenin for faithful gene
regulatory function and marked instability of the 23 kDa C-
terminal fragment (CTF) of PS-1. These aberrations are associated
with the down-regulation of major downstream transcription
factor effectors of Wnt regulation that are necessary for effective
generation of DA neurons, including Lmx1a and Engrailed 1
(En1). These findings are consistent with a working model of
HPRT-induced neuropathology in which the primary underlying
purine metabolic aberrations characteristic of HPRT deficiency
produce coordinate dysregulation of the key Wnt and PS-1
signaling pathways that in turn collaborate to cause aberrant
development of DA pathways and disturbed DA neurogenesis, at
least partly by dysregulating key neuronal transcription factors
necessary for faithful DA neural development. These findings may
provide a new understanding of the neuropathology associated
with human HPRT-deficiency and may point to new genetic or
metabolic targets for delineating the pathogenic mechanisms and
potential therapies for this and possibly other neurodevelopmental




The degree of HPRT gene knockdown in both the normal
human fibroblasts and the SH-SY5Y cells was approximately
90%, as estimated by quantitative PCR (qPCR) measurements
and Western blotting analysis (data not shown). Assays for HPRT
enzymatic activity showed a reduction of approximately ,75% in
the knockdown fibroblast cells and SH-SY5Y cells (data not
shown). The apparently slightly greater degree of transcriptional
knockdown of HPRT compared with HPRT protein and
quantitative HPRT enzyme activity may reflect the known high
level of HPRT protein stability and is consistent with results of a
previous study that reported a similar discrepancy between HPRT
transcription and protein level [27]. We consider the 90%
knockdown of HPRT gene expression to be sufficient to obtain
a useful picture of general transcriptional aberrations in HPRT
deficiency since we have previously demonstrated that knockdown
of this degree was sufficient to dysregulate DA neuron transcrip-
tion factor genes and to impair aspects of neurogenesis during in
vitro differentiation of NT2 cells toward the neuronal phenotype
[14].
Microarray studies
Of the 48,803 markers that we compared in the triplicate
experiments described in MATERIALS AND METHODS, we
detected a total of 286 genes whose expression was dysregulated by
a factor of .2-fold (Table S1). Of that total, 117 were up-
regulated and 169 were down-regulated in HPRT knockdown
fibroblasts. The down-regulated genes included the HPRT gene
that was down-regulated by 5.0–6.6 fold (Table S1), in general
agreement with the qPCR results of normal and knockdown cells
(above). The data demonstrated in this result have been deposited
in NCBI’s Gene Expression Omnibus and are accessible through
GEO Series accession number GSE24345 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE24345).
Gene ontology (GO) and gene set enrichment analysis
(GSEA)
A number of the major cellular processes dysregulated by
HPRT deficiency and identified by GO and GSEA analysis and
further characterized by the publicly available PANTHER
analytic software (www.pantherdb.org) are listed in Tables 1 and
Neural Regulatory Functions of HPRT
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function, the 286 differentially expressed genes were assigned to
established GO classifications by GeneSpring GX10. In this
classification, we found significantly aberrant 9 GO terms
(p,0.05), particularly those related to cellular surface regions or
cellular developmental processes (Table 1). For the results of
GSEA analysis, the 286 differentially expressed genes were
assigned to the functional gene sets of GSEA by GeneSpring
GX10. For this clustering, we used the relaxed false discovery rate
(FDR) of ,0.4 and p#0.1. With the relaxed FDR, we identified
three GSEA gene sets including Alzheimers_disease_dn (Table 1).
By means of GeneSpringGX10 analysis of all 286 dysregulated
genes indicated above, we consistently identified the Wnt pathway
to be one of the most consistently and significantly aberrant in
HPRT-deficient cells (Table 2). After analysis with PANTHER, a
number of additional pathways were also identified, including a
number of pathways relevant to neuronal function particularly
that of the Alzheimer’s disease/presenilin signaling pathway, as
indicated in Table 2. For the purposes of this present study, we
chose to focus on the Wnt and PS-1 pathways for further analysis,
as described below.
Dysregulated components of the canonical Wnt
signaling pathway
Because a major mediator of the canonical Wnt signaling is b-
catenin, we used Western blotting methods to characterize the
content and cellular localization of total and phosphorylated b-
catenin in control (Lux-ND) and HPRT knockdown SH-SY5Y
cells (sh2-ND) in the basal state and after 12 days of in vitro
differentiation, as illustrated in Figure 1. The left panels represent
cytosolic b-catenin while those on the right represent the nuclear
fractions. In the basal pre-differentiation state, control cells and
knockdown cells contain similar levels of cytosolic b-catenin,
although the content in knockdown cells is reproducibly slightly
reduced. A portion of the b-catenin in both cells is phosphorylated
and the amount of phosphorylated protein is markedly increased
in the knockdown cells, indicating an apparent increase in
phosphorylation of b-catenin in knockdown cells.
After a 12-day period of retinoic acid differentiation, total
cytosolic b-catenin in control cells is relatively unchanged,
although the amount of the phosphorylated form is moderately
reduced. In contrast, HPRT knockdown cells demonstrate a
marked increase in both total and phosphorylated cytosolic b-
catenin. Although differentiated control cells demonstrate a
significant degree of nuclear translocation of unphosphorylated
b-catenin, HPRT-knockdown cells reproducibly are markedly
deficient in nuclear translocation.
Effects of aberrant Wnt signaling on downstream
transcription factors
The canonical Wnt pathway is one of the key signaling
pathways that regulate expression of important transcription
factors such as Lmx1a and En1&2 that are necessary for DA
neuronogenesis. Because DA deficit is a hallmark defect in HPRT
deficiency and because we and other laboratories have previously
demonstrated that HPRT deficiency is accompanied by dysreg-
ulated expression of several of these important transcription factors
[13,14], including Lmx1a and En1&2, we examined the
expression of Lmx1a and En1 in basal and differentiated control
and knockdown cells (Figure 2). In both the undifferentiated and
the differentiated cells, expression of En1 and Lmx1a is markedly
reduced, to levels exceeding 50% in the case of Lmx1a in
differentiated cells. This result is consistent with a down-regulated
Wnt induction of expression of these transcription factors.
Aberrant PS-1 expression
The use of the PANTHER analytic method has identified the
Alzheimer’s disease/presenilin pathway to be the most severely
dysregulated pathway in the HPRT knockdown cells (Table 2).
Membrane-bound PS-1 is known normally to undergo proteolytic
cleavage into N-terminal fragment (NTF) of ca. 30 kDa and CTF
of ca. 20 kDa forms that then combine with other components in a
Table 1. Table 1 lists the entities identified by GO and GSEA of the 286 gene significantly aberrantly expressed (.2-fold) in HPRT
knockdown human fibroblasts.
GO accession GO Term *p-value
GO:0005576 extracellular region 7.63E-06
GO:0044421 extracellular region part 2.40E-05
GO:0005578 proteinaceous extracellular matrix 9.34E-05
GO:0031012 extracellular matrix 1.60E-04
GO:0022610 biological adhesion 5.27E-03
GO:0007155 cell adhesion 5.27E-03
GO:0048856 anatomical structure development 5.38E-03
GO:0032502 developmental process 5.38E-03
GO:0007275 multicellular organismal development 1.08E-02
Gene Set p-value [Control] vs [Knockdown] FDR ES NES
Brca_er_neg 0 0.13 -0.27 -1.4
Alzheimers_disease_dn 0.1 0.36 0.2 1.2
Stemcell_hematopoietic_up 0 0.38 0.27 1.44
The GO terms and GSEA gene sets are sorted by p-value and by false discovery rate (FDR), from smallest to largest, respectively. The p-values are marked by asterisks
and further described beneath the table.
*Benjamini-Yekutieil corrected p-value.
doi:10.1371/journal.pone.0016572.t001
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amyloid precursor protein (APP) to Ab. In some forms of familial
Alzheimer’s disease caused by PS-1 mutations, APP cleavage is
aberrant and produces increased levels of the toxic Ab42 cleavage
product that accumulates as amyloid deposits characteristic of
Alzheimer’s disease.
To further characterize the mechanism of dysregulated PS-1
expression in HPRT knockdown cells, we used Western blotting
methods to identify PS-1 expression in control SH-SY5Y cells
before and after differentiation (Figure 3). Both before and after 12
days of differentiation, the amounts of full-length PS-1 and of the
NTF protein are similar in the membrane fractions of control and
HPRT knockdown cells. In control cells, most of the PS-1 protein
exists in the form of the processed ,30 kDa NTF and 20–25 kDa
CTF. However, the HPRT-deficient cells reveal a virtually
complete absence of the 23 kDa form of the CTF. Since
production of the PS-1 protein and the overall processing seem
un-impaired, we interpret the loss of 23 kDa CTF to indicate
marked instability of that processed fragment of PS-1 in cells
deficient in HPRT expression.
Table 2. Table 2 lists the pathways identified by GeneSpring GX and Panther Classification System analysis for the 286 significantly
altered (,2-fold) genes in HPRT knockdown fibroblasts.
Predicted pathway by GeneSpring GX10 *p-value
Wnt 1.76E-02
Predicted pathway by Panther Classification System **p-value
Alzheimer disease-presenilin pathway 1.90E-06
Integrin signalling pathway 7.81E-05
Wnt signaling pathway 3.44E-04
Axon guidance mediated by Slit/Robo 1.67E-03
Cadherin signaling pathway 7.39E-03
Huntington disease 1.32E-02
Plasminogen activating cascade 1.85E-02
Angiogenesis 2.37E-02
Cytoskeletal regulation by Rho GTPase 2.71E-02
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway 4.34E-02
Inflammation mediated by chemokine and cytokine signaling pathway 4.59E-02




Figure 1. Western blot analysis of total and phosphorylated b-catenin in wild type and HPRT knockdown cells. Undifferentiated
control cells transduced with a control luciferase vector (lane 1), undifferentiated cells transduced with the HPRT knockdown vector (2), luciferase-
transduced cells at 12 days of differentiation (3) and HPRT-knockdown differentiated cells at 12 days of differentiation (4). Bottom panels represent
GAPDH and lamin loading controls.
doi:10.1371/journal.pone.0016572.g001
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NTF efficiently, we repeated the immunoblotting studies with a
second antibody specific for the NTF (see Methods). The results of
this study confirmed that the expression of the NTF in
undifferentiated HPRT-knockdown cells is indistinguishable from
that in control cells but that, in differentiated cells, the amount of
NTF is markedly reduced in both cell types, particularly in the
HPRT knockdown cells where NTF is virtually undetectable
(Figure 3).
In the present study, we have attempted to characterize a
potential physical interaction between Wnt/b-catenin and pre-
senilin-1. It is known that the CTF of PS-1 interacts with and
Figure 2. Quantitative PCR analysis of the neural transcription factors En1 and Lmx1a. In both the undifferentiated basal state and after
differentiation, there is marked reduction of expression of both transcription factors in the knockdown cells (filled columns). Error bars (Mean + SEM).
doi:10.1371/journal.pone.0016572.g002
Figure 3. Western blot analysis of PS-1 in wild type and HPRT-knockdown SH-SY5Y cells. Control SH-SY5Y cells were transduced by a
retrovirus vector encoding luciferase (Lux-ND) or the anti-HPRT shRNA (sh2-ND) before and after 12 days of differentiation with retinoic acid (Lux-D-
12 and sh2-D-12). The 55 kDa full-length PS-1 (FL PS1) and the 34 kDa NTF are present in approximately equal amounts in the undifferentiated
control and knockdown cells. After 12 days of differentiation, FL and NTF of PS-1 are markedly reduced. However, at both time, the 23 kDa form of
the CTF is markedly reduced in knockdown cells.
doi:10.1371/journal.pone.0016572.g003
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secretase activity does not affect PS-mediated regulation of b-
catenin [28]. To test the ability of PS-1 and b-catenin to interact
and to participate in formation of complexes that might shed light
on their coordinate dysregulation by HPRT, we used co-
immunoprecipitation methods to determine if HPRT deficiency
interferes with the ability of b-catenin and PS-1 function
coordinately in a complex. Figure 4 presents Western blots of
proteins precipitated either by anti-b-catenin or by anti-PS-1. In
both cases, we find that both proteins are immunoprecipitated by
either antibody, indicating that they are part of a common
complex and may thereby influence their joint functions. The
amounts of both proteins are moderately reduced after 12 days
differentiation, although the reduction is more pronounced in the
HPRT-knockdown cells.
As further validation of the aberrations of PS-1 signaling in
HPRT deficiency, we examined cultures of primary fibroblast
from 2 LND patients, one with no detectable residual HPRT
activity (WM) and one with 2.5% residual enzyme activity (LW).
Figure 5 illustrates the effect of HPRT deficiency on PS-1
expression in these cells compared with control normal human
fibroblasts (WT). Most of the PS-1 in WT cells is in the full-
length (FL) form and very little PS-1 protein is present either
as processed NTF or CTF. In contrast, both LND cells
demonstrate markedly increased levels of processed NTF and
CTF, indicating a markedly increased level of PS-1 proteolytic
processing or proteolytic fragment stability compared with WT
cells.
Discussion
The goals of this study were to identify mechanisms underlying
the mechanisms of dysregulated neurogenesis and aberrant DA
pathway development in HPRT-deficiency. While our present
results do not definitively identify mechanisms of neural disruption
in LND, they do identify for the first time several signaling
pathways that are markedly dysregulated in HPRT deficiency and
that represent important new targets for studying the mechanisms
of pathogenesis and possibly even of therapy for this disorder.
Because studies of aberrant gene expression in terminally
differentiated cells of different genetic backgrounds often fail to
clarify mechanisms that operate in less differentiated developing
systems such as those of the developing mammalian CNS, we
elected first to identify gene expression aberrations in HPRT-
knockdown human fibroblasts, then to validate them in HPRT-
deficient human DA cells such as the SH-SY5Y neuroblastoma
and then finally to validate candidate gene defects in cells derived
from LND patients. Toward these ends, we have used qPCR and
Western blotting methods to demonstrate that HPRT deficiency in
differentiating human neuroblastoma cells indeed does dysregulate
expression of several vital CNS neuronal and developmental
signaling pathways in which we had predicted dysregulated
expression by GO and GSEA analysis of microarray-based global
gene expression analyses of control and HPRT-knockdown
human fibroblasts. The extent to which these defects clarify
mechanisms of pathogenesis in LND patients is still to be
established, but these results demonstrate clearly in fully
Figure 4. Complexed b-catenin and PS-1 in wild type and HPRT-knockdown SH-SY5Y cells. SH-SY5Y cell proteins were
immunoprecipitated by antibody to PS-1 (upper panel) and to b-catenin (lower panel) and reacted with b-catenin or PS-1 antibodies. Un-
differentiated control cells transduced by luciferase vector (lane 1), undifferentiated HPRT-knockdown cells (lane 2), 12-day differentiated control cells
(lane 3) and 12-day HPRT-knockdown cells (lane 4).
doi:10.1371/journal.pone.0016572.g004
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dopaminergic SH-SY5Y neuroblastoma cells that HPRT plays
strong developmental roles in many functions and processes vital
for programs key to CNS development, a valuable insight into
HPRT neuronal regulatory function whether or not it fully
explains the disease phenotype. We conjecture that these robust
dysregulations in cultured HPRT-deficient cells may have
important neurologically deleterious effects in the human disease.
As we have confirmed by functional studies, the transcriptional
characterization of human fibroblasts knocked down for HPRT
expression through RNA interference has correctly identified
aberrations in HPRT deficiency of a number of important
signaling pathways, especially those identified in gene ontology
categories as the Wnt signaling and the Alzheimer’s disease/
presenilin pathways that play roles in the pathogenesis of two
common human neurodegenerative and neurodevelopmental
disease – Parkinson’s and Alzheimer’s diseases. Because we found
these pathways to be convincingly dysregulated in HPRT-
knockdown fibroblasts (Table 2), we extended the gene expression
analysis to another cell type; i.e., the SH-SY5Y neuroblastoma cell
line that can be differentiated into neuronal cells in vitro. The DA
SH-SY5Y neuroblastoma cells have served as valuable and
productive model systems to characterize mechanisms of neuro-
genesis in vitro and, in the present study, convincingly demon-
strate major disturbances of expression in HPRT knockdown cells
(Figures 1 and 3).
Our current study clearly demonstrates that knockdown of
HPRT leads to coordinate dysregulation of several vital signaling
pathways that play key roles in regulating aspects of neural
pathway development and neurogenesis and for that reason, are
attractive candidates for playing an important role in the
neurodevelopmental aberrations of LND. For these studies, we
have focused on two HPRT-regulated signaling pathways with
clear implications for neural function; e.g., the canonical Wnt and
the presenilin pathways. Many previous studies have revealed
important roles of Wnt signaling in the generation of DA pathways
and DA neurons. Of special interest is the known role of the Wnt/
b-catenin signaling pathway in regulating hippocampal and
midbrain DA neurogenesis [17–22]. It is also known that
treatment of prenatal DA progenitors with inhibitors of the b-
catenin kinase GSK3b enhances DA neurogenesis [29] and that
transplantation of rodent fetal neural stem cells treated with
Wnt5a results in enhanced survival, differentiation and functional
integration of stem cell-derived DA neurons in an animal model of
Parkinson’s disease [22]. As is clearly shown in Figure 1, HPRT
deficiency in SH-SY5Y cells impedes nuclear transport of cytosolic
b-catenin where it is required to carry out its gene regulatory roles.
To try to establish a possible direct relevance of these findings in
SH-SY5Y cells, we have examined several primary fibroblast
cultures from LND patients. In the case of b-catenin, we have so
far been unable to identify consistent aberrations in b-catenin
expression and nuclear transport, and we are pursuing those
studies with larger numbers of control and LND cells. Neverthe-
less, we infer from these results that the down-regulated Wnt
signaling pathway demonstrated in this study may contribute to
defective generation and function of DA neurons, possibly by
down-regulating downstream transcription factors such as Lmx1a
and En-1 (Figure 2) and others whose expression is necessary for
effective generation of DA neurons [18–21,30].
In the case of aberrant PS-1 signaling in HPRT-deficient SH-
SY5Y cells, we have found little change in the level of full-length or
NTF fragment of PS-1 in the HPRT-knockdown cells compared
with wild type cells, but virtual absence of the processed 23 kDa
CTF in membrane-fractions of HPRT knockdown SH-SY5Y cells,
both before and after retinoic acid differentiation (Figure 3). In
contrast, LND fibroblasts display little or no PS-1 processing in
Figure 5. Western blot analysis of PS-1 in fibroblasts from LND patients. WT cells demonstrate very low levels of PS-1 processing to the N-
and C-terminal fragment (NTF and CTF, respectively). In both LND cells, processing to both the NTF and CTF proteolytic products is markedly
increased compared with that seen in HPRT-positive control WT human fibroblasts.
doi:10.1371/journal.pone.0016572.g005
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NTF and CTF in the two patients fibroblast cells (Figure 5). These
aberrant PS-1 processing steps in HPRT-deficiency LND may
provide useful clues to previously unsuspected purinergic contri-
butions to defective processing of APP as found in familial
Alzheimer’s disease [25,26,31,33–35]. We interpret our results to
suggest that aberrant PS-1 processing in HPRT deficiency may
reveal additional mechanisms of neural damage other than the
Ab42 accumulation in Alzheimer’s Disease. The NTF and CTF of
PS-1 form a heterodimer that is normally incorporated into a
gamma-secretase complex whose aberrant function in some forms
of familial Alzheimer’s disease is implicated in aberrant APP
cleavage and over-production of toxic Ab42 or an increased ratio
of Ab42 to Ab40 [25]. It is the CTF of PS-1 that has been shown to
play a key role in determining pathogenicity in Ab42 accumula-
tion, since it has been shown that Ab42 accumulation does not
occur in cells expressing only the mutated NTF [32]. The
formation of the PS-1 heterodimer also has been reported to
enhance its stability. In the absence of heterodimer formation, it
has been thought that the pathogenic CTF is degraded and its
pathogenicity reduced or lost. Furthermore, phosphorylation of
the CTF of PS-1 [33], in particular the 23 kDa C-terminal isoform
has been also reported to decrease Ab production [34]. Our PS-1
results suggest that a decrease or loss of HPRT expression or
mimicking the altered purine levels and pool sizes in HPRT
deficiency may destabilize PS-1 heterodimer, allow the degrada-
tion of the CTF. We conjecture that purine modulations of purine
pathways may eventually provide avenues for therapy or
prevention of some neurodegenerative or neurodevelopmental
diseases associated with aberrant presenilin-1 function and/or Ab
processing.
As a further test of the functional significance of the PS-1 defect
in HPRT-knockdown cells and because PS-1 is known to regulate
Notch-1 signaling by cleaving Notch-1, we investigated the effect
of HPRT knockdown on the level of Notch intracellular cleavage
domain (NICD) in HPRT-deficient SH-SY5Y cells. Our prelim-
inary results indicate that while wild type and HPRT-deficient
SH-SY5Y cells have similar levels of NICD in the undifferentiated
state, retinoic acid-differentiated HPRT-deficient cells demon-
strate a marked (2.4 fold) decrease in NICD (Kang et al.,
unpublished results). We therefore infer from these results that
HPRT may therefore participate in regulating both APP and
Notch expression through its effect on PS-1 expression.
In the current case of HPRT effects on signaling pathways,
either one of these dysregulated pathways alone; i.e., Wnt
signaling and PS-1 expression, may reasonably play a role in at
least part of the HPRT deficiency neurological phenotype
through dysregulated expression of transcription factors or
through mechanisms related to disturbed PS-1 function and
gamma-secretase activity. In contrast, the individual roles of b-
catenin and PS-1 in neurodegenerative disease together with their
coordinate dysregulation by knockdown of the housekeeping gene
HPRT suggest that aberrant Wnt and PS-1 pathways may
interact and cooperate to produce pathogenic components that
individually are subtle but that in the aggregate produce
powerfully disrupting effects on vital neural pathways, such as
those seen in human HPRT deficiency. It may therefore not be a
surprise that the pathways regulating DA neuron development in
HPRT deficiency overlap with pathogenic mechanisms found in
severe neurodegenerative diseases such as Alzheimer’s and
Parkinson’s diseases. For instance, some defects in the generation
and function of DA neurons are obviously part of the Parkinson’s
disease phenotype but have also been reported in Alzheimer’s
disease. Loss of dopamine D2 receptors has been reported to play
both motor and cognitive roles in Alzheimer’s disease [36] and L-
dopa administration has been reported to produce a marked
reversal of the abnormalities of motor cortical excitability such as
decreased intra-cortical inhibition (ICI) in Alzheimer’s disease
patients [37].
Dysfunctional PS-1 has been reported to negatively regulate the
stability of b-catenin for regulating neuronal apoptosis or for
preventing neuronal differentiation [38,39]. This finding is
consistent with our finding that both non-differentiated and
differentiated HPRT-knockdown cells missing the 23 kDa CTF
show lower levels of b-catenin than control cells, possibly because
the b-catenin binding site on PS-1 is known to be on the C-
terminal portion of PS-1 (residues 322–450) [40]. The interaction
between b-catenin and PS-1 may suggest coordinate regulation
through formation of multifunctional complexes of these two and
possibly other components. Indeed, in our present study, we have
confirmed the reported interaction between PS-1 and b-catenin, as
demonstrated by co-immunoprecipitation with PS-1 and b-catenin
antibodies (Figure 4). The role played by dysfunctional PS-1 in
determining the stability and down-regulation of Wnt/b-catenin
signaling possibly through impaired complex formation between
b-catenin and truncated PS-1 merits further study.
Overall, we interpret our results to indicate that the molecular
and neurological phenotypes induced by HPRT deficiency
includes wide-spread pleitropic aberrations in components of
disparate major signaling pathways, especially dysregulated
neurodevelopmental processes associated with Wnt and PS-1
signaling pathways. The possible pathogenic role of individual
components of the Wnt/b-catenin and presenilin functions has not
previously been demonstrated experimentally to be associated with
the development of LND disease. The present study may therefore
point toward some common pathways among several quite
different neurodevelopmental and neurodegenerative disease and
suggest productive new areas of research to understand the
neurological defects in both these and other neurodegenerative-
and neurodevelopmental-disease.
Materials and Methods
Cells and in vitro neuronal differentiation
Human dermal fibroblast-adult (HDF-a) cells were obtained
from ScienCell Research Laboratories (ScienCell Research
Laboratories, Carlsbad, CA) and were grown to approximately
90% confluence in Dulbecco’s modified Eagle’s medium (DMEM)
high-glucose medium supplemented with 10% (v/v) fetal bovine
serum, 1% (v/v) penicillin/streptomycin (Invitrogen, Carlsbad,
CA) and 0.2% (v/v) normocin (Invivogen, San Diego, CA) in 5%
CO2 atmosphere. Medium was renewed every 2–3 days. Human
SH-SY5Y cells were obtained from ATTC and were maintained
as described above for HDF-a cells. Human SH-SY5Y cells
maintained in culture as described above were differentiated with
retinoic acid as previously described [41]. Two LND patient
fibroblast cells, WM and LW, were provided by Dr. H.A.
Jinnah. Department of Human Genetics and Pediatrics, Emory
University.
HPRT-knockdown and control vectors
The small hairpin oligonucleotides for HPRT knockdown were
selected as previously described [14]. The selected HPRT hairpin
oligonucleotides for this study are as follows: The sequence of the
sense element is 59-ATCCGTGGCCATCTGCTTAGTAGATT-
CAAGAGATCTACTAAGCAGATGGCCATTTTTTG-39 and
the sequence of anti-sense element is 59-ATTTCAAAAAATG-
GCCATCTGCTTAGTAGATCTCTTGAATCTACTAAGCA-
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sequence is underlined. The selected hairpin oligonucleotides were
recombined with RNAi-Ready pSIREN Moloney leukemia virus-
based retrovirus vectors that express shRNA from the human U6
promoter (Clontech Laboratories, Mountain View, CA), and the
pSIREN vectors and plasmid encoding the glycoprotein of
vesicular stomatitis virus (pCMV-G) were co-transfected into the
packaging cell line GP-293 [14]. The viral titer, production and
isolation from packaging cell line GP-293 were carried out in HT-
1080 cells as previously described [14]. As a control shRNA, we
used an RNAi-Ready pSIREN-RetroQ vector (Clontech Labora-
tories) expressing a shRNA retrovirus vector targeted against
luciferase.
Cell transduction and selection of HPRT-deficient cells
Control and knockdown cells were infected at a multiplicity of
infection (MOI) of approximately 1 with anti-luciferase or anti-
HPRT vectors retroviral vectors. Infected cells were grown for 10
days in complete DMEM medium containing 3 ug/ml of
puromycin. Bulk cultures were re-plated and maintained in
DMEM without puromycin selection for an additional 7 days,
after which cells were examined for HPRT expression by transfer
to DMEM containing 250 uM 6-thioguanine. The cells infected
with the HPRT shRNA retrovirus vector grew and expanded
normally in 6-thioguanine, whereas the control cells infected with
luciferase shRNA were unable to grow in 6-thioguanine (data not
shown).
RNA purification and quantitative PCR analysis
Total RNAs from HPRT-knockdown and control cells were
purified by RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instruction. To synthesize
complementary DNAs from purified RNA, 2 ug of total RNA
were applied to the mixture of TaqMan reverse transcription
reagents (Applied Biosystems, Foster City, CA) consisting of
5.5 mM MgCl2, 500 uM dNTP mixture, 2.5 uM random
hexamer, 0.4 U/ml RNase inhibitor and 1.25 U/ml reverse
transcriptase in 50 ul of TaqMan RT buffer. Thermal cycling
for reverse transcription included activation at 25uC for 10
minutes, reverse transcription at 48uC for 30 minutes and
inactivation at 95uC for 5 minutes. For qPCR analysis, the
reagents required for the PCR reaction were supplied from a
Qiagen QuantiTect SYBR Green PCR Kit (Qiagen) and the PCR
reaction was carried out using the Opticon2 System DNA Engine
(BioRad, Hercules, CA). Primer sequences for these reactions are
summarized in Table S2. For normalization of qPCR, primers
specific for the housekeeping gene TATA box binding protein as
well as the glyceraldehyde-3-phosphate dehydrogenase were used
as a standardization control.
Immunoblotting
For protein extraction, HPRT-knockdown and control cells
were lysed by Mammalian Cell Lysis Kit (Sigma-Aldrich, St.
Louis, MO) according to the manufacturer’s instructions. For the
subcellular fractionation of proteins, HPRT-knockdown and
control SH-SY5Y cells and LND patient fibroblast cells were
lysed and fractionated by Qproteome Cell Compartment Kit
(Qiagen) according to the manufacturer’s instructions. Extracted
proteins were quantified by the Bradford protein assay. Twenty
or Ten microgram protein samples were separated by reducing-
Tricine-SDS-PAGE and the separated protein bands were
transferred onto polyvinylidene fluoride membrane (Millipore,
Billerica, MA) using Mini Trans-Blot Electrophoretic Transfer
Cell (BioRad). Blotted polyvinylidene fluoride membranes were
blocked by blocking solution containing 1% bovine serum
albumin, 20 mM of Tris, 137 mM of NaCl and 0.1% of
Tween-20 (Sigma-Aldrich) for one hour at room temperature.
Immunodetection of primary antibodies was carried out over-
night in a 4uC chamber and signal amplification using
horseradish peroxidase-conjugated secondary antibody was
performed at room temperature for one hour. As the chemilu-
minescence reagent, SuperSignal West Pico (Thermo Scientific,
Rockford, IL) was treated and the x-ray film was developed by
SRX101A film processor (Konica Minolta, Motosu-shi, Gifu-
ken). The monoclonal antibody for HPRT (Santa Cruz
Biotechnology, Santa Cruz, CA) was used for immunostaining,
using goat anti-mouse IgG-HRP (Thermo Scientific) as the
secondary antibody. Antibodies for b-catenin, phospho-b-catenin
and full length and C-terminal fragment of presenilin-1 were
obtained from Cell Signaling Technologies (Danvers, MA) and
the antibody for N-terminal fragment of presenilin-1 was
purchased from Abcam (Cambridge, MA). Mouse monoclonal
antibody to beta-actin (Abcam) and antibodies to GAPDH and
Lamin A/C (Cell Signaling Technology) were used as the loading
controls. All primary and secondary antibodies were diluted in
blocking solution according to manufacturer’s instructions. For
the co-immunoprecipitation, cells were lysed by 1X cell lysis
buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4 and
1X protease inhibitor cocktail (Roche, Basel, Switzerland). Before
immunoprecipitation, the 500 ul of lysate were pre-cleaned by
incubation with the 50 ul of protein A agarose beads (50% of
bead slurry) at 4uC for 60 minutes. After pre-cleaning, the 500 ul
of cell lysate was incubated with anti-b-catenin or anti-presenilin
1 primary antibody at 4uC for overnight. For precipitation of
proteins coupled with primary antibody, the 50 ul of protein A
agarose beads (50% of bead slurry) was added and incubated with
gentle rocking for three hours at 4uC. The precipitate was washed
with 500 ul of 1X cell lysis buffer five times and the proteins
coupled with protein A agarose beads were eluted by reducing
sample buffer for Western-blotting.
HPRT enzymatic assay
HPRT assays were performed as described [42]. To measure
the activity of HPRT, HPRT-knockdown and control cells were
treated with lysis buffer (10 mM Tris-HCl, pH 7.4 and 12.5 mM
MgCl2) and sonicated on ice six times for 10 seconds each interval
of 30 seconds. Aliquots of 50 ug of extracted proteins were added
to the assay mixture consisting of 2 mM hypoxanthine, 2 mM
adenine (Sigma-Aldrich), 0.12 mM [8-
14C] hypoxanthine,
0.12 mM [8-
14C] adenine (Moravek Biochemicals, Brea, CA),
0.24 mM AOPCP and 5 mM PRPP (Sigma-Aldrich), and the
assay mixtures were further incubated at 37uC for 2 hr. The
enzyme reactions were stopped by adding trichloroacetic acid
(Sigma-Aldrich) to a final concentration of 2.5% and the
supernatants were collected after centrifugation at 10,000 xg for
5 minutes. Aliquots of 3 ul of carrier consisting of 19.1 mM AMP
and IMP (1:1 ratio) from Sigma-Aldrich were spotted onto TLC
PEI Cellulose F (EMD Chemicals, Gibbstown, NJ) plates, and 3 ul
aliquots of the sample supernatant were applied to the plates.
Ascending chromatography was carried with 5% Na2HPO4
(Sigma-Aldrich) as a solvent and the chromatogram was air-dried.
Chromatograms were exposed for 24–48 hours to x-ray film at
270uC. Portions of the plates corresponding to the positions of
IMP and AMP were scraped, transferred to scintillation vials and
radioactivity was measured using a Beckman LS 6500 liquid
scintillating counter (Beckman Coulter, Brea, CA).
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All reported data are MIAME compliant and that the raw data
have been deposited in NCBI’s Gene Expression Omnibus (Edgar
et al., 2002) and are accessible through GEO Series accession
number GSE24345 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE24345).a MIAME compliant database (E.g.
ArrayExpress, GEO), as detailed on the MGED Society website.
For microarray analysis, RNAs from triplicate independent
cultures of vector-infected HPRT knockdown and control
fibroblasts were prepared separately, pooled and used to prepare
cRNA and finally subjected to microarray transcriptional analysis
in triplicate. The integrity of total RNA from HPRT knockdown
and control cells was confirmed by bioanalyzer (Agilent Technol-
ogies, Santa Clara, CA). The quality of total RNA samples from
HPRT knockdown and control cells was assessed by 2100
bioanalyzer [43] before application to microarray analysis. We
determined that the RNA integrity number (RIN) [44], (maximal
degradation =1; maximal molecular integrity =10) was 10 for
both the normal and knockdown cells (data not shown), indicating
that isolated RNA samples were of sufficiently high quality to
permit subsequent preparation of cDNA for microarray analysis.
Microarray transcriptional analysis was performed in triplicate
using the HumanWG-6 v3.0 Expression BeadChip system
(Illumina, San Diego, CA). All reagents were obtained from
HumanWG-6 v.3 Expression BeadChip Kit (Illumina) and all
experimental processes were carried out according to manufac-
turer’s instruction (Illumina). After scanning of hybridized
BeadChip, quantitation of slide images were performed using
Illumina’s BeadArray software and the raw data were normalized
by Loess normalization method [45], and then the normalized raw
data in BeadStudio was exported to GeneSpring GX 10.0.2
(Agilent, Santa Clara, CA). For identification of genes significantly
altered in knockdown cell compared with the control normal gene
set, total detected entities were filtered by signal intensity value
(upper cut-off 100
th and lower cut-off 20
th percentile) and error
(coefficient of variation: CV ,50.0 percent) to remove very low
signal entities and to select reproducible signal values of entities
among the replicated experiments, respectively. In statistical
analysis, t-test unpaired (p,0.05) was applied and all significant
changes above 2-fold were selected. Signals were selected if they
were above microarray background (detection p-value ,0.05) in
either all six experiments or in at least three knockdown or control
experiments. Analysis of GO, GSEA and signaling pathway [46-
48] was carried out using GeneSpring GX 10.0.2 (Agilent) and the
PANTHER Classification System (http://www.pantherdb.org/).
In the analysis of signaling pathways using GeneSpring GX 10.0.2
(Agilent), a total of 140 cellular pathways were identified. For
GSEA analysis, we used the false discovery rate (FDR) of ,0.4 and
p#0.1.
Supporting Information
Table S1 The list of significantly changed 286 entities (.2-fold)
(XLS)
Table S2 Primer sequences used for qPCR
(XLS)
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